Policy & Regulation
DualityBio agrees global collaboration and licensing deal with Genentech
28 August 2026 - Clinical-stage biopharmaceutical company Duality Biotherapeutics Inc (DualityBio) (HKEX: 09606) announced on Friday that it has entered into a collaboration and licence agreement with...
AbbVie seeks EMA approval for subcutaneous induction of risankizumab in Crohn's disease
27 August 2026 - US biopharmaceutical company AbbVie (NYSE: ABBV) announced on Thursday that it has applied to the European Medicines Agency for approval of subcutaneous induction dosing of SKYRIZI (r...
Natera and Angiex partner to assess AGX101 response using Signatera
27 August 2026 - Cell-free DNA and precision medicine company Natera Inc (NASDAQ:NTRA) announced on Thursday that it has entered into a collaboration with privately held biotech company Angiex Inc to ...
AstraZeneca and Amgen report Tezspire met primary endpoints in Phase III EoE trial
27 August 2026 - Biopharmaceutical companies AstraZeneca plc (STO:AZN) (LON:AZN) (NYSE:AZN) and Amgen Inc (NASDAQ:AMGN) on Thursday reported positive results from the Phase III CROSSING trial showing ...
ReviR Therapeutics' RTX-117 receives FDA Rare Pediatric Disease Designation for Charcot-Marie-Tooth disease
27 August 2026 - Clinical-stage biotechnology company ReviR Therapeutics announced on Wednesday that the US Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to ...
Graviton BioScience reports positive trial results for GV101 in chronic Graft versus Host Disease
27 August 2026 - Clinical-stage biotechnology company Graviton BioScience Corporation announced on Wednesday the publication of peer-reviewed data from a multicentre Phase Ib/II multi-dose, open-label...